When was Corcept founded?

Corcept was founded in 1998 and raised its 1st funding round 8 years after it was founded.

Where is Corcept located?

Corcept is headquartered in Menlo Park, United States.

How many employees does Corcept have?

As of May 31, 2026, the latest employee count at Corcept is 772.

Is Corcept a funded company?

Corcept is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Nov 15, 2006.

When was the latest funding round of Corcept?

Corcept's latest funding was a $***** Post IPO round on 2011, with participation from 1 investor.

What is the annual revenue of Corcept?

Annual revenue of Corcept is between $500M and $1B as on Dec 31, 2025

Where does Corcept rank among its competitors?

Corcept ranks 2nd amongst 42 active competitors, of which 9 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Sernova, which secured $345K in Oct, 2025.

Who are the top competitors of Corcept?

Corcept's top competitors include MannKind Corp, 89bio and Rhythm Pharmaceuticals. Among them, Sernova secured the most recent funding round in October, 2025.

Corcept - 2026 Company Profile, Team, Funding, Competitors & Financials

Corcept is a public company based in Menlo Park (United States), founded in 1998 by Joe Belanoff. It operates as a Developer of cortisol modulators for the treatment of various diseases. Corcept has raised an undisclosed amount in funding. The company has 42 active competitors, including 9 funded and 19 that have exited. Its top competitors include companies like MannKind Corp, 89bio and Rhythm Pharmaceuticals.

Company Details

Developer of cortisol modulators for the treatment of various diseases. The company focuses on the discovery and development of drugs that modulate the effects of cortisol that target glucocorticoid receptor (GR) antagonists to treat a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases.

Website: corcept.com
Social

Key Metrics

Founded Year

1998

Location

Menlo Park, United States

Stage

Public

Latest Funding Round

Post IPO, 2011, $*****

Investors

Cornerstone Capital & 7 more

Ranked

2^nd among 42 active competitors

Annual Revenue

$500M - $1B as on Dec 31, 2025

Employee Count

772 as on May 31, 2026

Similar Companies

MannKind Corp & 58 more

Exit Details

Public

View Corcept's full profile

Corcept is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CORCEPT THERAPEUTICS INCORPORATION CIN: 77-0487658 , United States, Active	Dec 31, 1997	-	352 (As on Dec 31, 2023)	-
Corcept Therapeutics Inc CIN: 1088856 , United States, Active	May 12, 1998	$500M - $1B (As on Dec 31, 2025)	-	-

Corcept got listed on Jan 05, 2004.

Click here to take a look at Corcept's IPO in detail

Corcept has raised funding over 6 rounds. Its first funding round was on Nov 15, 2006. Its latest funding round was a Post IPO round on 2011 for $*****. 1 investor participated in its latest round. Corcept has 8 institutional investors.

Here is the list of recent funding rounds of Corcept:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
2011	6211	Post IPO	6026	3192	7141	7358
Apr 30, 2010	9476755	Post IPO	9195893	6200624	1875740	4200960
Oct 13, 2009	9533655	Post IPO	4770419	5551205	7064065	6384897

Access funding benchmarks and valuations. Sign up today!

View details of Corcept's funding rounds and investors

The founders of Corcept is Joe Belanoff.

Here are the details of Corcept's key team members:

Joe Belanoff: Co-Founder & CEO of Corcept.

View details of Corcept's Founder profiles and Board Members

Corcept's employee count trend

Corcept has 772 employees as of May 26. Here is Corcept's employee count trend over the years:

Uncover Corcept's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Corcept include MannKind Corp, 89bio and Rhythm Pharmaceuticals. Here is the list of Top 10 competitors of Corcept, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Deerfield & 1 others	72/100
2nd	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Cornerstone Capital, Investor Growth Capital ... & 6 others	68/100
3rd	89bio 2018, San Francisco (United States), Acquired	Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders	$60M	Orbimed, Longitude Capital & 3 others	67/100
4th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Third Rock Ventures, Pfizer Venture Investments ... & 8 others	66/100
5th	Sernova 1998, London (Canada), Public	Regenerative medicine to deliver proteins and hormones for disease treatment	-	National Research Council Canada, Evotec & 1 others	62/100
6th	Genfit 1999, Loos (France), Public	Therapeutics for cardiometabolic and neurodegenerative diseases.	-	Ridgeback Capital Management, Eiffel Investment Group ... & 2 others	58/100
7th	OptiBiotix Health 2012, York (United Kingdom), Public	Developer of microbial strains for the treatment of human metabolic diseases	-	Seneca EIS Portfolio Fund, Mercia & 2 others	55/100
8th	NGM Biopharmaceuticals 2007, San Francisco (United States), Public	Developer of biologics for the treatment of cardio-metabolic and liver disease	$359M	The Column Group, Prospect Venture Partners ... & 7 others	54/100
9th	ViaCyte 1999, San Diego (United States), Acquired	Developer of cell therapy for the treatment of diabetes	$389M	Bain Capital Life Sciences, Sanderling Ventures ... & 21 others	54/100
10th	PhaseBio Pharmaceuticals 2002, Malvern (United States), Public	Developer of novel drugs to treat metabolic and cardiopulmonary disorders	$152M	New Enterprise Associates, Rock Springs Capital ... & 12 others	50/100